David Baskin Download Headshot

David Baskin, MD, FAANS, FACS

  • Houston Methodist neurosurgeon
  • Director of the Houston Methodist Kenneth R. Peak Brain & Pituitary Tumor Treatment Center
  • Vice chairman, Houston Methodist Hospital department of neurosurgery
  • Residency program director, Houston Methodist Hospital department of neurosurgery
  • Professor of neurological surgery, Weill Cornell Medical College
Media Contact: Patti Muck , 832.667.5740

David Baskin, MD, FAANS, FACS

Request Interview
Media Contact: Patti Muck , 832.667.5740

Areas of Expertise

  • Astrocytomas 
  • Brain and spinal cord tumors
  • Endoscopy
  • Glioblastomas
  • Metastatic brain and spinal tumors
  • Microsurgery of the brain and spine
  • Minimally invasive brain surgery using endoscopy and virtual reality
  • Novel treatments &  clinical trials for brain tumors
  • Pituitary tumors
  • Skull base tumors
  • Stereotactic radiosurgery

Credentials

BOARD CERTIFICATION
American Board of Neurological Surgery
MEDICAL SCHOOL
Mount Sinai School of Medicine of the CUNY | 1978
FELLOWSHIP
Research in Brain Endorphins-San Francisco,CA | 1984
Research in Neural Protection-Cape Town, South Africa | 1982
RESIDENCY
University of California, San Francisco - San Francisco, CA | 1984
INTERNSHIP
University of California, San Francisco - San Francisco, CA | 1978

Publications

Advances in gene therapy for high-grade glioma: a review of the clinical evidence
Goldman, MJ, Baskin, AM, Sharpe, MA & Baskin, DS 2024, , Expert Review of Neurotherapeutics, vol. 24, no. 9, pp. 879-895. https://doi.org/10.1080/14737175.2024.2376847

Letter to the Editor Response: LETTERS TO THE EDITOR RESPONSE
Stuebe, CM, Jenson, AV, Lines, TW, Holloman, AM, Cykowski, MD, Fung, SH, Fisher, RE, McClain, KL & Baskin, DS 2024, , Journal of Neurosurgery: Case Lessons, vol. 7, no. 9, CASE23667. https://doi.org/10.3171/CASE23667

Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells
Hambarde, S, Manalo, JM, Baskin, DS, Sharpe, MA & Helekar, SA 2023, , Scientific Reports, vol. 13, no. 1, 19264, pp. 19264. https://doi.org/10.1038/s41598-023-46758-w

Retinal Hemifield Slide Phenomenon as a Presenting Symptom of Pituitary Abscess 2 Months After Pituitary Adenoma Resection
Schwartz, L, Raviskanthan, S, Mortensen, PW, Baskin, DS & Lee, AG 2023, , Journal of Neuro-Ophthalmology, vol. 43, no. 4, pp. E217-E218. https://doi.org/10.1097/WNO.0000000000001439


International Tuberculum Sellae Meningioma Study: Surgical Outcomes and Management Trends
on behalf of the International Tuberculum Sellae Meningioma Study Authors 2023, , Neurosurgery, vol. 93, no. 6, pp. 1259-1270. https://doi.org/10.1227/neu.0000000000002569

EXTH-05 - Anti-tumor immune response of Oncomagnetic monotherapy in glioblastoma
Pandey, A, Hambarde, S, Baskin, DS & Helekar, S 2023, , 28th Annual Meeting of Society for NeuroOncology, Vancouver, Canada, 11/15/23 - 11/19/23.

Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells
Hambarde, S, Manalo, JM, Baskin, DS, Sharpe, MA & Helekar, SA 2023, , Scientific Reports, vol. 13, no. 1, pp. 19264. https://doi.org/10.1038/s41598-023-46758-w

Recurrent petit mal seizures in Erdheim-Chester disease mimicking an intra-axial brain tumor: illustrative case
Stuebe, CM, Jenson, AV, Lines, TW, Holloman, AM, Cykowski, MD, Fung, SH, Fisher, RE, McClain, KL & Baskin, DS 2023, , Journal of Neurosurgery: Case Lessons, vol. 6, no. 16, CASE23248. https://doi.org/10.3171/CASE23248

Oscillation patterns for oncomagnetic treatment
Helekar, S, Baskin, DS, Sharpe, MA & Pichumani, K Apr. 13 2023, , Patent No. WO2023060149A1.

Method and apparatus for oncomagnetic treatment
Helekar, S, Baskin, DS, Sharpe, MA & Pichumani, K Feb. 09 2023, , Patent No. 20230043685.

Method and apparatus for oncomagnetic treatment
Helekar, S, Baskin, DS, Sharpe, MA & Pichumani, K Feb. 07 2023, , Patent No. US11571585B2.

Acquisition of Immune Privilege in GBM Tumors: Role of Prostaglandins and Bile Salts
Sharpe, MA, Baskin, DS, Johnson, RD & Baskin, AM 2023, , International journal of molecular sciences, vol. 24, no. 4, 3198. https://doi.org/10.3390/ijms24043198

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extension of Survival among Patients with Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
Liau, LM, Ashkan, K, Brem, S, Campian, JL, Trusheim, JE, Iwamoto, FM, Tran, DD, Ansstas, G, Cobbs, CS, Heth, JA, Salacz, ME, DAndre, S, Aiken, RD, Moshel, YA, Nam, JY, Pillainayagam, CP, Wagner, SA, Walter, KA, Chaudhary, R, Goldlust, SA, Lee, IY, Bota, DA, Elinzano, H, Grewal, J, Lillehei, K, Mikkelsen, T, Walbert, T, Abram, S, Brenner, AJ, Ewend, MG, Khagi, S, Lovick, DS, Portnow, J, Kim, L, Loudon, WG, Martinez, NL, Thompson, RC, Avigan, DE, Fink, KL, Geoffroy, FJ, Giglio, P, Gligich, O, Krex, D, Lindhorst, SM, Lutzky, J, Meisel, HJ, Nadji-Ohl, M, Sanchin, L, Sloan, A, Taylor, LP, Wu, JK, Dunbar, EM, Etame, AB, Kesari, S, Mathieu, D, Piccioni, DE, Baskin, DS, Lacroix, M, May, SA, New, PZ, Pluard, TJ, Toms, SA, Tse, V, Peak, S, Villano, JL, Battiste, JD, Mulholland, PJ, Pearlman, ML, Petrecca, K, Schulder, M, Prins, RM, Boynton, AL & Bosch, ML 2023, , JAMA oncology, vol. 9, no. 1, pp. 112-121. https://doi.org/10.1001/jamaoncol.2022.5370

INNV-12. Reproducible reductions of contrast-enhanced tumor volumes in two end-stage recurrent glioblastoma patients with in-home Oncomagnetic monotherapy
Helekar, S & Baskin, DS 2022, , Society for Neuro-Oncology 27th Annual Meeting, Tampa, United States, 11/16/22 - 11/20/22 pp. vii143.

EXTH-65. Synergistic oncolytic effects of temozolomide and Oncomagnetic therapies in glioblastoma.
Pandey, A, Hambarde, S, Baskin, DS & Helekar, S 2022, , Society for Neuro-Oncology 27th Annual Meeting, Tampa, United States, 11/16/22 - 11/20/22 pp. vii224.

EXTH-68. Oncomagnetic treatment selectively kills glioma cancer cells by inducing oxidative stress and DNA damage.
Hambarde, S, Pandey, A, Baskin, DS & Helekar, S 2022, , Society for Neuro-Oncology 27th Annual Meeting, Tampa, United States, 11/16/22 - 11/20/22 pp. vii224-vii225.

METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, SA, Baskin, DS, Sharpe, MA & Pichumani, K Jun. 23 2022, , Patent No. US2022193436.

Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors
George, J, Chen, Y, Abdelfattah, N, Yamamoto, K, Gallup, TD, Adamson, SI, Rybinski, B, Srivastava, A, Kumar, P, Lee, MG, Baskin, DS, Jiang, W, Choi, JM, Flavahan, W, Chuang, JH, Kim, BY, Xu, J, Jung, SY & Yun, K 2022, , Cancer research communications, vol. 2, no. 6, pp. 402-416. https://doi.org/10.1158/2767-9764.crc-22-0124

Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
George, J, Chen, Y, Abdelfattah, N, Yamamoto, K, Gallup, TD, Adamson, SI, Rybinski, B, Srivastava, A, Kumar, P, Lee, MG, Baskin, DS, Jiang, W, Choi, JM, Flavahan, W, Chuang, JH, Kim, BYS, Xu, J, Jung, SY & Yun, K 2022, , Cancer research communications, vol. 2, no. 6, pp. 402-416. https://doi.org/10.1158/2767-9764.CRC-22-0124

Languages

  • English